E. Kipps, D. Tan, and S. B. Kaye, Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research, Nat Rev Cancer, vol.13, issue.4, pp.273-82, 2013.

S. Banerjee and S. B. Kaye, New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential, Clin Cancer Res Off J Am Assoc Cancer Res, vol.19, issue.5, pp.961-969, 2013.

N. Auersperg, A. S. Wong, K. C. Choi, S. K. Kang, and P. C. Leung, Ovarian surface epithelium: biology, endocrinology, and pathology, Endocr Rev, vol.22, issue.2, pp.255-88, 2001.

R. F. Ozols, M. A. Bookman, D. C. Connolly, M. B. Daly, A. K. Godwin et al., Focus on epithelial ovarian cancer. Cancer Cell, vol.5, issue.1, p.14749123, 2004.

K. Borden and B. Culjkovic-kraljacic, Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond? Leuk Lymphoma, vol.51, pp.1805-1820, 2010.

J. Kai, Y. Wang, F. Xiong, and S. Wang, Genetic and pharmacological inhibition of eIF4E effectively targets esophageal cancer cells and augments 5-FU's efficacy, J Thorac Dis, vol.10, issue.7, pp.3983-91, 2018.

S. Kö-ké-ny, J. Papp, G. Weber, T. Vaszkó, P. Carmona-saez et al., Ribavirin acts via multiple pathways in inhibition of leukemic cell proliferation, Anticancer Res, vol.29, issue.6, pp.1971-80, 2009.

I. Topisirovic, M. Ruiz-gutierrez, and K. Borden, Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities, Cancer Res, vol.64, issue.23, pp.8639-8681, 2004.

F. Pettersson, C. Yau, M. C. Dobocan, B. Culjkovic-kraljacic, H. Retrouvey et al., Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer, Clin Cancer Res Off J Am Assoc Cancer Res, vol.17, issue.9, pp.2874-84, 2011.

W. Li, F. Shen, and G. Weber, Ribavirin and quercetin synergistically downregulate signal transduction and are cytotoxic in human ovarian carcinoma cells, Oncol Res, vol.11, issue.5, pp.243-250, 1999.

S. Assouline, B. Culjkovic-kraljacic, J. Bergeron, S. Caplan, E. Cocolakis et al., A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E, Haematologica, vol.100, issue.1, pp.7-9, 2015.

R. A. Youcef, D. Santos, M. Roussel, S. Baltaze, J. Lubin-germain et al., Huisgen cycloaddition reaction of C-alkynyl ribosides under micellar catalysis: synthesis of ribavirin analogues, J Org Chem, vol.74, issue.11, pp.4318-4341, 2009.

C. Solarte, M. D. Santos, S. Gonzalez, L. Miranda, R. Guillot et al., Synthesis of C-Ribosyl-1,2,3-triazolyl Carboxamides, Synthesis, vol.49, issue.9, pp.1993-2002, 2017.

F. Cosson, A. Faroux, J. Baltaze, J. Farjon, R. Guillot et al., Synthesis of ribavirin 2'-Me-C-nucleoside analogues, Beilstein J Org Chem, vol.13, pp.755-61, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02141294

D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation, Cell, vol.144, issue.5, pp.646-74, 2011.

T. J. Shaw, M. K. Senterman, K. Dawson, C. A. Crane, and B. C. Vanderhyden, Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer, Mol Ther J Am Soc Gene Ther, vol.10, issue.6, pp.1032-1074, 2004.

J. Schindelin, I. Arganda-carreras, E. Frise, V. Kaynig, M. Longair et al., Fiji: an open-source platform for biological-image analysis, Nat Methods, vol.9, issue.7, pp.676-82, 2012.

L. Carduner, J. Leroy-dudal, C. R. Picot, O. Gallet, F. Carreiras et al., Ascites-induced shift along epithelial-mesenchymal spectrum in ovarian cancer cells: enhancement of their invasive behavior partly dependant on ?v integrins, Clin Exp Metastasis, vol.31, issue.6, p.24946950, 2014.

S. Kellouche, J. Fernandes, J. Leroy-dudal, O. Gallet, S. Dutoit et al., Initial formation of IGROV1 ovarian cancer multicellular aggregates involves vitronectin, Tumor Biol, vol.31, issue.2, pp.129-168, 2010.

L. Carduner, C. R. Picot, J. Leroy-dudal, L. Blay, S. Kellouche et al., Cell cycle arrest or survival signaling through ?v integrins, activation of PKC and ERK1/2 lead to anoikis resistance of ovarian cancer spheroids, Exp Cell Res, vol.320, issue.2, pp.329-371, 2014.

L. Heyman, S. Kellouche, J. Fernandes, S. Dutoit, L. Poulain et al., Vitronectin and its receptors partly mediate adhesion of ovarian cancer cells to peritoneal mesothelium in vitro, Tumour Biol, vol.29, issue.4, pp.231-275, 2008.

M. Villedieu, M. Briand, M. Duval, J. F. Hé-ron, P. Gauduchon et al., Anticancer and chemosensitizing effects of 2,3-DCPE in ovarian carcinoma cell lines: link with ERK activation and modulation of p21WAF1/CIP1, Bcl-2 and Bcl-xL expression, Gynecol Oncol, vol.105, issue.2, pp.373-84, 2007.

C. Xi, L. Wang, J. Yu, H. Ye, L. Cao et al., Inhibition of eukaryotic translation initiation factor 4E is effective against chemo-resistance in colon and cervical cancer, Biochem Biophys Res Commun, vol.503, issue.4, pp.2286-92, 201818.

A. Kentsis, I. Topisirovic, B. Culjkovic, L. Shao, and K. Borden, Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap, Proc Natl Acad Sci, vol.101, issue.52, pp.18105-18115, 2004.

K. Tan, B. Culjkovic, A. Amri, and K. Borden, Ribavirin targets eIF4E dependent Akt survival signaling, Biochem Biophys Res Commun, vol.375, issue.3, pp.341-346, 2008.

S. Assouline, B. Culjkovic, E. Cocolakis, C. Rousseau, N. Beslu et al., Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin, Blood, vol.114, issue.2, pp.257-60, 2009.

J. Tó-vári, J. Bocsi, A. Ladá-nyi, K. Lapis, and J. Timár, The antitumor effect of Tiazofurin (TR) consists of antiproliferative and anti-invasive elements, Anticancer Res, vol.16, issue.6A, pp.3307-3319, 1996.

K. Zaoui, S. Honoré, D. Isnardon, D. Braguer, and A. Badache, Memo-RhoA-mDia1 signaling controls microtubules, the actin network, and adhesion site formation in migrating cells, J Cell Biol, vol.183, issue.3, pp.401-409, 2008.

F. Carreiras, V. Rigot, S. Cruet, F. André, P. Gauduchon et al., Migration properties of the human ovarian adenocarcinoma cell line IGROV1: Importance of ?v?3 integrins and vitronectin, Int J Cancer

, , vol.80, pp.285-94, 19990118-01-18.

J. Leroy-dudal, C. Demeilliers, O. Gallet, E. Pauthe, S. Dutoit et al., Transmigration of human ovarian adenocarcinoma cells through endothelial extracellular matrix involves alphav integrins and the participation of MMP2, Int J Cancer, vol.114, issue.4, pp.531-574, 2005.

L. Heyman, J. Leroy-dudal, J. Fernandes, D. Seyer, S. Dutoit et al., Mesothelial vitronectin stimulates migration of ovarian cancer cells, Cell Biol Int, vol.34, issue.5, pp.493-502, 2010.

F. Pettersson, D. Rincon, S. V. Emond, A. Huor, B. et al., Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis. Cancer Res, vol.75, pp.1102-1114, 2015.

M. Michaelis, R. Michaelis, T. Suhan, H. Schmidt, M. A. Doerr et al., Ribavirin inhibits angiogenesis by tetrahydrobiopterin depletion, FASEB J Off Publ Fed Am Soc Exp Biol, vol.21, issue.1, pp.81-88, 2007.

M. Stoeck, S. Miescher, H. R. Macdonald, V. Fliedner, and V. , Transforming growth factors beta slow down cell-cycle progression in a murine interleukin-2 dependent T-cell line, J Cell Physiol, vol.141, issue.1, pp.65-73, 1989.

H. X. Chao, C. E. Poovey, A. A. Privette, G. D. Grant, H. Y. Chao et al., Orchestration of DNA Damage Checkpoint Dynamics across the Human Cell Cycle, Cell Syst, vol.5, issue.5, pp.445-459, 201722.

J. Fidorra, T. Mielke, J. Booz, and L. E. Feinendegen, Cellular and nuclear volume of human cells during the cell cycle, Radiat Environ Biophys, vol.19, issue.3, pp.205-219, 1981.

P. Roca-cusachs, J. Alcaraz, R. Sunyer, J. Samitier, R. Farré et al., Micropatterning of single endothelial cell shape reveals a tight coupling between nuclear volume in G1 and proliferation, Biophys J, vol.94, issue.12, pp.4984-95, 2008.

D. M. Kochhar, J. D. Penner, and T. B. Knudsen, Embryotoxic, teratogenic, and metabolic effects of ribavirin in mice, Toxicol Appl Pharmacol, vol.52, issue.1, pp.99-112, 1980.

J. P. Thiery, H. Acloque, R. Huang, and M. A. Nieto, Epithelial-mesenchymal transitions in development and disease, Cell, vol.139, issue.5, pp.871-90, 2009.

N. Ahmed, K. Abubaker, J. Findlay, and M. Quinn, Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets, vol.10, pp.268-78, 2010.

D. Vergara, B. Merlot, J. Lucot, P. Collinet, D. Vinatier et al., Epithelial-mesenchymal transition in ovarian cancer, Cancer Lett, vol.291, issue.1, pp.59-66, 2010.